NCT03366792 is a NA clinical trial of Artemis™ software system in Prostate Cancer, sponsored by NYU Langone Health.

Who is sponsoring NCT03366792?

NCT03366792 is sponsored by NYU Langone Health.

What drugs are being tested in NCT03366792?

Interventions in NCT03366792: Artemis™ software system.

What condition does NCT03366792 study?

NCT03366792 studies Prostate Cancer.

Is NCT03366792 still recruiting?

NCT03366792 is currently terminated. Last updated 23 March 2022.

Are results published for NCT03366792?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-03-23 · How we verify

NCT03366792

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer

Terminated NA Results posted Last updated 23 March 2022

What this trial tests

NA trial testing Artemis™ software system in Prostate Cancer in 46 participants. Terminated before completion.

Timeline

17 October 2017

Primary endpoint
26 February 2021

26 February 2021

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	46
Start date	17 October 2017
Primary completion	26 February 2021
Estimated completion	26 February 2021
Sites	1 location across United States

Drugs / interventions tested

Artemis™ software system

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 40 to 85, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Core Cancer Length Primary · 2 Months

Greater tumor length per core provides better diagnostic information. Data is reported as Transperineal (TP) core cancer length, Transrectal (TR) core cancer length, and for both (TP+TR)

Group	Value	95% CI
MRI Targeted Biopsy	5	1.875 – 6.75

Group	Value	95% CI
MRI Targeted Biopsy	6	2.1 – 7.75

TP+TR

Group	Value	95% CI
MRI Targeted Biopsy	5	1.95 – 7.25

Percentage of High-Grade Prostate Cancer Using Gleason Score Secondary · 2 Months

High-grade prostate cancer is defined as a Gleason score \> 6; a score that is the sum of the two Gleason grades assigned to a prostate tumor and that is based on a scale of 2 to 10 with the lowest numbers indicating a slow-growing tumor unlikely to spread and the highest numbers indicating an aggressive tumor. Data is reported as a percentage for Transperineal (TP), Transrectal (TR), and for both (TP+TR)

Group	Value	95% CI
MRI Targeted Biopsy	34

Group	Value	95% CI
MRI Targeted Biopsy	40

TP+TR

Group	Value	95% CI
MRI Targeted Biopsy	49

Adverse events — posted to ClinicalTrials.gov

Time frame: 2 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

MRI Targeted Biopsy

Serious: 0/46 (0%)

Deaths: 0/46

Other adverse events (1 terms — click to expand)

Reaction	System	MRI Targeted Biopsy
Hematuria	Renal and urinary disorders	—

Data from ClinicalTrials.gov NCT03366792 adverse events section.

Sponsor's own description

The purpose of this study is to investigate a transperineal biopsy approach (outside of the rectum) using MRI targeting to facilitate better access to the whole prostate gland and provide limited risk of infectious complications after biopsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03366792 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 23 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing